Monday, 20 May 2019

You are here

Drug Pricing Regulations in US and Canada

Reuters reports on regulatory efforts by Canada and the US to curb the rising cost of drugs, especially expensive new medicines. 

In Canada, a little-known government agency is increasing its oversight of expensive drugs sold in Canada. The federal Patented Medicine Prices Review Board (PMPRB) is targeting an increasing number of expensive drugs introduced in the last several years by drug makers.

This  agency has the authority to review and challenge the price of any such drugs in Canada and may order companies to repay some revenue.  A review of open PMPRB investigations finds that the use of overpriced drugs has more than doubled from 59 in 2013 to 122 as of March 2018.

The PMPRB aims to contain costs to the benefit of private drug plans, provincial governments and out-of-pocket costs for the patients.

Of course the concern is that these practices in Canada may be considered in Washington, as yet another way of controlling drug prices.

Lobbyists for the pharmaceutical industry have suggested that the changes can delay or limit Canadians’ access to new patented medicines.

Reuters reported in February that drug companies offered to give up C$8.6 billion($6.4 billion) in revenue over 10 years to head off the PMPRB reforms. 

Announced in 2017, the rules were scheduled to take effect in January but have been delayed as the government reviews feedback.

A second Reuters report discusses the transparency of drug pricing with the Trump administration plans to require drugmakers to disclose drug prices with direct to consumer advertisements (DTCA) for promoted drugs. (Citation source: https://buff.ly/2H5G76i)

In an effort to lower drugs costs for consumers, U.S. Department of Health and Human Services (HHS) says that the list price would be disclosed if it is equal to or greater than $35 for a month’s supply.  HHS Secretary Alex Azar said the agency settled on the $35 a month benchmark because that is a common copayment paid by patients filling their monthly prescriptions.

 HHS says that the 10 most commonly advertised drugs range from $488 to $16,938 per month.

This is one of two efforts to reduce prices; a recently proposed rule requires that drug rebates, or discounts, be passed on to Medicare patients when they buy certain drugs.

This advertising rule, which was finalized on Wednesday, will take effect in about 60 days.

 

 

 

 

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Rheumatologists' Comments

Thanks for sharing Dr Cush.. Like usual, the ones who are responsible for the issues use the argument that are politically correct: "Lobbyists for the pharmaceutical industry have suggested that the changes can delay or limit Canadians’ access to new patented medicines". We all know the bottom hidden agenda. These issues may need to have input and involvement from the main players and sufferers: the doctors and patients, maybe via some sort of voting mechanism

More Like This

Generic Price Fixing Alleged by State Prosecutors

The NY Times and 60 Minutes have reported that Connecticut, along with 43 other states, filed a mega-lawsuit accusing the generic drug makers of a massive, systematic conspiracy to bilk consumers out of billions of dollars. (Citation source: https://buff.ly/2vSmv03)

Nonadherence is Costly for Patients in Pain

A comparative cohort study of patients with osteoarthritis (OA), gout, diabetic peripheral neuropathy (pDPN), post-herpetic neuralgia (PHN), and fibromyalgia (FM) shows that nonadherence to pain medications is high and leads to greater overall health care resource utilization and costs. 

Naproxen has no Effect on Alzheimer's

A randomized controlled trial shows that chronic low-dose naproxen does not reduce progression of presymptomatic Alzheimer disease (AD).

The INTREPAD trial was a 2-year double-masked prevention trial, that enrolled 195 AD who were randomized 1:1 to naproxen sodium 220 mg twice daily or placebo. The primary outcome was rate of change in a multimodal composite presymptomatic Alzheimer Progression Score (APS).

Timing of Shoulder Injections Impacts Surgical Infection Risk

A study of patients undergoing arthroscopic rotator cuff repair shows that corticosteroid injections in the month prior to surgery are associated with a significantly increased risk of surgical site infection.

Dietary Supplements Fail to Reduce Mortality Risks

An NIH funded prospective study has shown that the use of daily dietary supplements was not associated with a subsequent lowering of mortality risk.